Organization
Teva Pharmaceutical Industries Ltd.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Teva Pharmaceutical Industries Ltd.
... Mylan N.V. (NASDAQ, TASE: MYL) today announced that Teva has dismissed its pending district court litigation against Mylan regarding Mylan's Glatiramer ...
... Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive launch of ...
... per pill, compared to $65 per pill for the brand-name drug. Teva Pharmaceutical Industries is also launching a generic version of Viagra today. ( Medscape ...
... It’s no secret that Teva’s about to unveil some major layoffs. And the tally could reportedly reach ...
... without having to actually modify the underlying genome. (Los Angeles Times) INDICATIONS Teva may cut up to 10,000 jobs in massive restructure. Embattled generic drug ...
... Global Bulk Drug Raw Materials Procurement Market Intelligence Report 2017 Featuring Merck, Teva, Pfizer, AstraZeneca & BASF - Research and Markets ...
... in the interim report for January-September 2017, the partnership agreements with Teva Pharmaceutical Industries Ltd and NeoTX Therapeutics Ltd have a decisive impact on the ...
... branded Viagra, according to the Associated Press. The move comes as Teva Pharmaceutical Industries gets the green light to compete with the legendary brand nearly ...
... $32.50 per pill—half the usual $65 price tag. Also on the 11th, Teva Pharmaceuticals is set to release a generic version of the pill, as ...
... players profiled in this market include Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., AstraZeneca plc, Pfizer, Inc., Amgen Inc., Kissei Pharmaceutical ...
... end of each week. TevaCSO Michael Hayden will leave. A shakeup at Teva was expected when Kåre Schultz, who pushed for a rejig at Lundbeck, ...
... Active Biotech and Teva’s laquinimod—once billed as a successor to multiple sclerosis blockbuster Copaxone—has hit yet ...
... Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the publication of data ...
... 150 medical oncologists, the report covers 7 major therapies from Kyowa Kirin, Teva, Takeda, and Mundipharma/Napp. Handy graphs and charts show you how 7 barriers ...
... survey of 100 medical oncologists, the report covers 6 major therapies from Teva, Mallinckrodt, Endo Pharmaceuticals, Purdue Pharma and Insys Therapeutics. Handy graphs and charts ...
... treatments for Parkinson's Disease from AbbVie, Britannia, GSK, Lundbeck, Meda Pharma, Novartis, Teva, UCB and Zambon. It shows: · How physicians rate each team overall, ...
... for the 12 leading treatments for Parkinson's Disease from AbbVie, GSK, Impax, Teva, Novartis, Pfizer, UCB, US World Meds and Valeant. It shows: · How ...
... Teva Pharmaceutical Industries shares rose Monday after the drugmaker said it was shaking up ...
Want to see the full history of news? Upgrade to RelSci Professional now!
Start My Free Trial